Don Darkin - ResMed President
| RMD Stock | USD 185.09 0.77 0.41% |
President
Mr. Don Darkin is President innovation operations of Resmed Inc. Previously Mr. Darkin was president sleepdisordered breathing strategic business unit a position he began in May 2011 and senior vice president strategic business unit patient interfaces from July 2007 to May 2011. Before these positions Mr. Darkin held several senior roles within ResMed. He joined ResMed in August 1999 as vice president product development. In May 2005 he became director of operations in France for ventilation and subsequently served as vice president business divisions and senior vice president global product development. Before working at ResMed Mr. Darkin served as vice president of operations for Ambri Pty Ltd. Australia and vice president product development for Telectronics Medical Systems Australia and US. Mr. Darkin is identified as an inventor or coinventor on over 80 granted patents worldwide. Mr. Darkin was educated in the UK in mechanical engineering and has further professional management training from University of New South Wales and Massachusetts Institute of Technology. since 2014.
| Age | 61 |
| Tenure | 10 years |
| Address | 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 |
| Phone | 858-836-5000 |
| Web | https://www.resmed.com |
ResMed Management Efficiency
The company has Return on Asset of 0.1119 % which means that on every $100 spent on assets, it made $0.1119 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2166 %, implying that it generated $0.2166 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. As of April 16, 2024, Return On Tangible Assets is expected to decline to 0.13. In addition to that, Return On Capital Employed is expected to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 477.5 M, whereas Deferred Long Term Asset Charges is forecasted to decline to about 42.6 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert Breighner | Select Medical Holdings | 55 | |
| Peter Mantegazza | Encompass Health Corp | N/A | |
| Kevin Reese | The Ensign Group | N/A | |
| John Saich | Select Medical Holdings | 55 | |
| Julia Powell | National HealthCare | 68 | |
| Linda Wilder | Encompass Health Corp | N/A | |
| Thomas Mullin | Select Medical Holdings | 40 | |
| Jeffrey Smith | National HealthCare | 61 | |
| Michael Ussery | National HealthCare | 65 | |
| Michael Tarvin | Select Medical Holdings | 63 | |
| Frank Brown | Encompass Health Corp | N/A | |
| B Flatt | National HealthCare | 57 | |
| Spencer Burton | The Ensign Group | 45 | |
| Jerry Gray | Encompass Health Corp | N/A | |
| David Lassiter | National HealthCare | 59 | |
| John Lines | National HealthCare | 57 | |
| Martin Jackson | Select Medical Holdings | 69 | |
| Brian Kidd | National HealthCare | 49 | |
| R Ussery | National HealthCare | 60 | |
| Scott Romberger | Select Medical Holdings | 63 | |
| Barbara Jacobsmeyer | Encompass Health Corp | 55 | |
Management Performance
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.11 |
ResMed Inc Leadership Team
Elected by the shareholders, the ResMed's board of directors comprises two types of representatives: ResMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ResMed. The board's role is to monitor ResMed's management team and ensure that shareholders' interests are well served. ResMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ResMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bobby Ghoshal, Chief Technology Officer, President - SaaS business | ||
| AM BE, Chair Founder | ||
| John Wareham, Independent Director | ||
| Ronald Taylor, Lead Independent Director | ||
| Michael Rider, Chief Officer | ||
| Gary Pace, Independent Director | ||
| Agnes Lee, Senior Director - Investor Relations | ||
| Vered Keisar, Chief Officer | ||
| Harjit Gill, Independent Director | ||
| Kaushik Ghoshal, Chief SaaS | ||
| Carol Burt, Independent Director | ||
| Rich Sulpizio, Independent Director | ||
| Peter Farrell, Non-Executive Chairman of the Board | ||
| Jim Hollingshead, President – sleep and respiratory care business | ||
| Don Darkin, President - Sleep-disordered Breathing Strategic Business Unit | ||
| Jack Wareham, Independent Director | ||
| Jan Witte, Independent Director | ||
| Rajwant Sodhi, President – Software as a Service Business (SaaS) | ||
| BE MBA, CEO Director | ||
| Anne Reiser, President Europe | ||
| Karen Drexler, Independent Director | ||
| AM AM, Founder Chairman | ||
| Richard McHale, President – Respiratory Care Business | ||
| Donald Darkin, President – innovation & operations | ||
| Constance Bienfait, Director Relations | ||
| Urvashi Tyagi, Chief Technology Officer | ||
| Rob Douglas, President COO | ||
| Justin Leong, President – Asia and Latin America | ||
| Christopher Roberts, Independent Director | ||
| Chris Roberts, Independent Director | ||
| Robert Douglas, President, Chief Operating Officer | ||
| YvonneKatrin Pucknat, Chief Officer | ||
| Amy Wakeham, VP Communications | ||
| Brett Sandercock, CFO and Principal Accounting Officer | ||
| Ron Taylor, Lead Independent Director | ||
| Raj Sodhi, President – Software as a Service (SaaS) Business and CTO | ||
| David Pendarvis, Chief Administrative Officer, Global General Counsel, Secretary | ||
| Richard Sulpizio, Independent Director | ||
| Michael Farrell, Chief Executive Officer, Director | ||
| Jim Ellis, Chief Officer |
ResMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ResMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 28.51 B | ||||
| Shares Outstanding | 147.09 M | ||||
| Shares Owned By Insiders | 0.81 % | ||||
| Shares Owned By Institutions | 57.18 % | ||||
| Number Of Shares Shorted | 7.89 M | ||||
| Price To Earning | 73.48 X |
ResMed Investors Sentiment
The influence of ResMed's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in ResMed. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to ResMed's public news can be used to forecast risks associated with an investment in ResMed. The trend in average sentiment can be used to explain how an investor holding ResMed can time the market purely based on public headlines and social activities around ResMed Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ResMed's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ResMed's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average ResMed's news discussions. The higher the estimated score, the more favorable is the investor's outlook on ResMed.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ResMed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ResMed's short interest history, or implied volatility extrapolated from ResMed options trading.
Currently Active Assets on Macroaxis
| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink | |
| XLM | Stellar | |
| CRO | Cronos |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for ResMed Stock analysis
When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
Is ResMed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Dividend Share 1.84 | Earnings Share 6.04 | Revenue Per Share 30.633 | Quarterly Revenue Growth 0.125 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.